
## **Supplementary Materials**



iguie of i towerait angiant.	Figure	S1.	Flowchart	diagram.
------------------------------	--------	-----	-----------	----------

Table S1. STROBE Statement – checklist of items that should be included in reports of observational studies.

	Item No	Recommendation	Paragraph numbers in section*
Title and abstract		(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract Section 2
	1	(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract Section 2–3
		Introduction	
Background/rationale	Explain the scientific background and rationale for the investiga-		1–2–3
Objectives		State specific objectives, including any prespecified hypotheses	4
		Methods	
Study design	4	Present key elements of study design early in the paper	Demographics and endpoints paragraphs
Setting	5	Describe the setting, locations, and relevant dates, including peri- ods of recruitment, exposure, follow-up, and data collection	Demographics para- graph
Participants	6	Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow- up. Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed. Case-control study—For matched studies, give matching criteria and the number of controls per case	

Variables	7	Clearly define all outcomes, exposures, predictors, potentia founders, and effect modifiers. Give diagnostic criteria, if ap ble		
Data sources/ meas- urement	8*	For each variable of interest, give sources of data and deta methods of assessment (measurement). Describe comparabi assessment methods if there is more than one group		
Bias	9	Describe any efforts to address potential sources of bia	S	
Study size	10	Explain how the study size was arrived at	NA for this retrospec- tive study	
Quantitative variables	5 11	Explain how quantitative variables were handled in the ana If applicable, describe which groupings were chosen and	5 5	
		(a) Describe all statistical methods, including those used to c for confounding	control Statistical analysis paragraph	
		(b) Describe any methods used to examine subgroups and in tions	nterac- Statistical analysis paragraph	
		(c) Explain how missing data were addressed	ND	
Statistical methods	12	(d) Cohort study—If applicable, explain how loss to follow-u addressed	ıp was	
		Case-control study—If applicable, explain how matching of and controls was addressed	paragraph	
		Cross-sectional study—If applicable, describe analytical me	thods	
		taking account of sampling strategy		
		( <u>e</u> ) Describe any sensitivity analyses		
		Results		
(8	a) Repo	ort numbers of individuals at each stage of study—e.g. num-		
	ers po	tentially eligible, examined for eligibility, confirmed eligible, luded in the study, completing follow-up, and analyzed	Supplementary figure 1 (CONSORT diagram)	
		(b) Give reasons for non-participation at each stage	Supplementary figure 1 (CONSORT diagram)	
		(c) Consider use of a flow diagram	Supplementary figure 1 (CONSORT diagram)	
Ca	al, soci	characteristics of study participants (e.g. demographic, clini- al) and information on exposures and potential confounders	Demographics paragraph and Table 1	
Descriptive data 14*	) Indio	cate number of participants with missing data for each varia- ble of interest	Table 1	
(c	) Cohc	ort study—Summaries follow-up time (e.g., average and total amount)	Eribulin efficacy on BCBM paragraph	
	Coho	rt study—Report numbers of outcome events or summary measures over time	Eribulin efficacy on BCBM paragraph	
	Case-co	ontrol study—Report numbers in each exposure category, or summary measures of exposure	NA	
	Cross-s	ectional study—Report numbers of outcome events or sum- mary measures	NA	
Main regulte 16 —	usted o lake clo	ve unadjusted estimates and, if applicable, confounder-ad- estimates and their precision (e.g., 95% confidence interval). ear which confounders were adjusted for and why they were included	Eribulin efficacy on BCBM paragraph, Figure 1, and ta- ble 2	
Main results 16 (b	) Repo	ort category boundaries when continuous variables were cat- egorized	Eribulin efficacy on BCBM paragraph and table 2	
-	) If re	levant, consider translating estimates of relative risk into ab-	NA	

Other analyses	17	Report other analyses done—e.g. analyses of subgroups and interac- tions, and sensitivity analyses	Other survival endpoints paragraph, Figures 2 and 3, and table 3			
		Discussion				
Key results	18	Summaries key results with reference to study objectives	1st paragraph			
Limitations	19	Discuss limitations of the study, taking into account sources of po- tential bias or imprecision. Discuss both direction and magnitude of any potential bias	5th paragraph			
Interpretation	20	Give a cautious overall interpretation of results considering objec- tives, limitations, multiplicity of analyses, results from similar stud- ies, and other relevant evidence	Paragraphs 2 to 4 and con- clusion			
Generalizabil- ity	21	Discuss the generalizability (external validity) of the study results	Conclusion section			
Other information						
Funding		Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Done			

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/ (accessed on 12 March 2021), Annals of Internal Medicine at http://www.annals.org/ (accessed on 12 March 2021), and Epidemiology at http://www.epidem.com/ (accessed on 12 March 2021)). Information on the STROBE Initiative is available at www.strobe-statement.org (accessed on 12 March 2021).